Kenvue (NYSE:KVUE) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Kenvue (NYSE:KVUE) posted its earnings results on Thursday. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01), FiscalAI reports. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same period in the previous year, the company posted $0.29 EPS. Kenvue’s revenue was up 3.0% on a year-over-year basis.

Kenvue Stock Performance

Kenvue stock traded down $0.59 during mid-day trading on Thursday, reaching $19.08. 25,099,333 shares of the company were exchanged, compared to its average volume of 20,800,660. Kenvue has a twelve month low of $14.02 and a twelve month high of $21.96. The firm’s 50-day simple moving average is $18.73 and its two-hundred day simple moving average is $18.08. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The firm has a market cap of $36.63 billion, a PE ratio of 22.45, a price-to-earnings-growth ratio of 1.49 and a beta of 0.47.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Analysts Set New Price Targets

Several brokerages recently weighed in on KVUE. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen raised Kenvue to a “buy” rating in a research note on Sunday, July 12th. Finally, UBS Group upped their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.58.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.59% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KVUE. Transamerica Financial Advisors LLC raised its holdings in Kenvue by 80.4% during the fourth quarter. Transamerica Financial Advisors LLC now owns 11,083 shares of the company’s stock worth $191,000 after purchasing an additional 4,939 shares during the last quarter. SmartHarvest Portfolios LLC purchased a new position in shares of Kenvue in the fourth quarter valued at $198,000. Sittner & Nelson LLC increased its position in shares of Kenvue by 410.0% in the third quarter. Sittner & Nelson LLC now owns 10,200 shares of the company’s stock valued at $166,000 after buying an additional 8,200 shares in the last quarter. Brooklyn Investment Group raised its stake in shares of Kenvue by 48.8% during the 3rd quarter. Brooklyn Investment Group now owns 11,355 shares of the company’s stock worth $184,000 after buying an additional 3,724 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Kenvue during the 3rd quarter worth $176,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.